GGrantIndex
← Leaderboards

William K. Kelly

Yale University

$4,165,697
Attributed
$7,178,482
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200825
$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,178,482 · 7

By mechanism

R01$4,966,455 · 2
P30$2,212,027 · 5

Top collaborators

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsMalignant NeoplasmsResearch PersonnelMonitorClinical ResearchTranslational ResearchMalignant Neoplasm Of ProstateCancer CenterCellsReportingFundingProgramsBaseCollaborationsInvestigator-Initiated TrialLaboratoriesMemberUniversitiesClinical ManagementLeadershipEnsurePeer ReviewPopulation BasedProtocols Documentation

Grant awards (27)

Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$653,812
R01 · FY2025 · CA
Clinical Protocol and Data Management$454,585
P30 · FY2025 · CA · contact PI
Protocol Review and Monitoring$64,179
P30 · FY2025 · CA · contact PI
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$607,916
R01 · FY2024 · CA
Clinical Protocol and Data Management$425,690
P30 · FY2024 · CA · contact PI
Protocol Review and Monitoring$60,101
P30 · FY2024 · CA · contact PI
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$626,097
R01 · FY2023 · CA
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$596,405
R01 · FY2022 · CA
Prostate Cancer$48,775
P30 · FY2022 · CA · contact PI
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer$693,113
R01 · FY2021 · CA
Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer$357,405
R01 · FY2021 · CA
Prostate Cancer$48,775
P30 · FY2021 · CA · contact PI
Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer$357,405
R01 · FY2020 · CA
Prostate Cancer$48,775
P30 · FY2020 · CA · contact PI
Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer$346,682
R01 · FY2019 · CA
Clinical Protocol and Data Management$181,876
P30 · FY2019 · CA · contact PI
Prostate Cancer$48,775
P30 · FY2019 · CA · contact PI
Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer$360,198
R01 · FY2018 · CA
Clinical Protocol and Data Management$181,876
P30 · FY2018 · CA · contact PI
Prostate Cancer$48,775
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$11,841
P30 · FY2018 · CA · contact PI
Prostate Cancer$11,841
P30 · FY2018 · CA · contact PI
Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer$367,422
R01 · FY2017 · CA
Shared Resources-Clinical Research Services$138,419
P30 · FY2011 · CA · contact PI
Shared Resources-Clinical Research Services$155,758
P30 · FY2010 · CA · contact PI
Shared Resources-Clinical Research Services$140,993
P30 · FY2009 · CA · contact PI
Shared Resources-Clinical Research Services$140,993
P30 · FY2008 · CA · contact PI